Congress orders audit of federal biotech workforce gaps

What it does

This bill directs the Office of Personnel Management to work with 14 federal agencies (Agriculture, Commerce, Defense, Energy, HHS, Homeland Security, Interior, State, Treasury, EPA, NASA, NSF, Intelligence, and Trade) to assess their current and future biotechnology workforce needs over the next 5 and 10 years. The assessment will identify how many biotechnology positions exist, how many are filled, what qualifications are needed, security clearance requirements, and gaps in hiring or training. Within 180 days, the Director must report findings to Congress, including recommendations for recruiting, training, and retaining biotech talent through internal development, inter-agency transfers, outside expert pools, and public-private talent exchanges.

Why we flagged it

The bill is a straightforward directive to assess biotechnology workforce capacity across federal agencies. It contains no spending authority, no new regulations, no restrictions, and no private-sector carve-outs. It is a planning and transparency instrument.

What the text implies

• The assessment may reveal significant security-clearance bottlenecks in biotech hiring, potentially leading to future appropriations requests for expedited vetting.
• Public-private talent exchanges (Section 3(b)(14)) could create pathways for federal biotech employees to move to private industry and vice versa, affecting brain drain and private-sector influence on federal research.
• The bill's focus on 'outside expertise' and 'prequalified expert pools' (Section 3(b)(13)) may lay groundwork for expanded use of contractors and consultants in federal biotech work, shifting labor from permanent staff to contingent workers.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill itself creates no direct benefit or cost to ordinary citizens—it is a fact-finding and planning measure. However, the underlying policy goal (strengthening federal biotech workforce capacity) could serve public interests (biosecurity, pandemic preparedness, agricultural innovation) or could facilitate government biotech activities that citizens might view differently depending on their values. The bill is neutral on implementation and does not mandate spending or restrict rights.

Named in the bill

Office of Personnel Management, Department of Agriculture, Department of Commerce, Department of Defense, Department of Energy, Department of Health and Human Services, Department of Homeland Security, Department of the Interior, Department of State, Department of the Treasury, Environmental Protection Agency, National Aeronautics and Space Administration — and 5 more

Where it stands

2 cosponsors: 2 Republicans.

• May 20, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 20, 2026 — Referred to House Committee on Oversight and Government Reform · Congress.gov: “Referred to the House Committee on Oversight and Government Reform”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.